- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Marksans Pharma has announced an addendum to its upcoming Annual General Meeting notice. Shareholders will now consider an additional special resolution to approve the re-appointment of Mr. Mark Saldanha as Managing Director for a five-year term, starting October 6, 2025. His annual remuneration is proposed at Rs. 6 Crore, along with perquisites. Mr. Saldanha, key to the company's growth with over two decades of experience, is seen as crucial for future success. This move aims to ensure continuity in leadership and strategy, important for long-term shareholder value.